Regeneron

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Regeneron and other ETFs, options, and stocks.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

13,450

Employees13,450

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

13,450

Employees13,450

REGN Key Statistics

Market cap

77.13B

Market cap77.13B

Price-Earnings ratio

17.37

Price-Earnings ratio17.37

Dividend yield

—

Dividend yield—

Average volume

1.05M

Average volume1.05M

High today

$717.61

High today$717.61

Low today

$698.65

Low today$698.65

Open price

$710.20

Open price$710.20

Volume

1.89M

Volume1.89M

52 Week high

$1,211.20

52 Week high$1,211.20

52 Week low

$693.00

52 Week low$693.00

REGN News

Seeking Alpha 2d

Regeneron reports positive results for two anti-coagulant drugs

Regeneron (NASDAQ:REGN) reported positive Phase 2 data for its thrombosis drug candidates REGN7508 and REGN9933 and plans to initiate Phase 3 testing next year....

Benzinga 4d

Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study

On Tuesday, Regeneron Pharmaceuticals, Inc. REGN announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD (aflibercept) Injecti...

Seeking Alpha 4d

Regeneron posts Phase 3 win for Eylea HD in retinal vein occlusion

Regeneron (NASDAQ:REGN) announced Tuesday that Eylea HD, the high-dose version of its blockbuster eye care medication Eylea marketed with Bayer (OTCPK:BAYZF), r...

Analyst ratings

68%

of 28 ratings

Buy

67.9%

Hold

28.6%

Sell

3.6%